LXRX vs T · rev $21.8M vs P/E 7.4, rev $63.06B
Lexicon Pharmaceuticals Inc (LXRX) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
Latest reported T revenue for 2026-06-30 was $63.06B. Net income was $8.46B. T currently screens at market cap $155.92B and trailing P/E 7.4.
LXRX currently screens at market cap $327.2M. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the LXRX and T stock pages for the full models.
Not investment advice.